Avantor

Digital Transformation And Rising Costs Will Undermine Lab Chemicals Sector

AnalystLowTarget

Not Invested

Consensus Narrative from 17 Analysts

Published

20 Apr 25

Updated

20 Aug 25

AnalystLowTarget's Fair Value

US$12.00

10.6% overvalued

20 Aug

US$13.27

-48.3%

2.6%

Author's Valuation

US$12.0

10.6% overvalued

AnalystLowTarget Fair Value

Narrative

Updates2

Shared on30 Apr 25
Fair value Decreased 14%

Shared on23 Apr 25

AnalystLowTarget Fair Value

US$12.0

10.6% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

2.39%

Life Sciences revenue growth rate

0.33%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.11%

Calculation

US$459.83m

Earnings '28

22.58x

PE Ratio '28

US$10.38b

Market Cap '28

US$10.38b

Market Cap '28

685.13m

No. shares '28

US$15.16

Share Price '28

US$15.16 Share Price '28

Discounted to 2025 @ 8.10% p.a.

US$12.00

Fair Value '25

Digital Transformation And Rising Costs Will Undermine Lab Chemicals Sector

Shared on30 Apr 25Fair value Decreased 14%

Shared on23 Apr 25

Shared on30 Apr 25
Fair value Decreased 14%